angiotensin ii , human

Angiotensin II human (Ang II) is a biologically active peptide, a vasoconstrictor. Angiotensin II interacts with AT1R and AT2R to regulate blood pressure, stimulate sympathetic nerves, and increase aldosterone biosynthesis and renal activity in humans.

Angiotensin II human acetate (DRVYIHPF acetate) is a vasoconstrictor that mainly acts on the AT1 receptor.

Angiotensin II (5-8) is an endogenous C-terminal fragment of the peptide vasoconstrictor angiotensin II

Angiotensin II is a potent direct vasoconstrictor, causing arteries and veins to constrict, so leading to an increase in blood pressure. Angiotensin also potentiates the release of norepinephrine by a direct action on postganglionic sympathetic fibers.

Angiotensin II (3-8), human is a less effective agonist at the angiotensin AT1 receptor.

Angiotensin II human TFA, a potent vasoconstrictor within the renin/angiotensin system, plays a pivotal role in human blood pressure regulation primarily through interactions with the G-protein-coupled receptors Angiotensin II type 1 receptor (AT1R) and Angiotensin II type 2 receptor (AT2R). It not only prompts sympathetic nervous stimulation, aldosterone biosynthesis, and renal effects but also fosters growth in vascular smooth muscle cells and boosts collagen type I and III synthesis in fibroblasts. This action results in the thickening of the vascular wall and myocardium, alongside fibrosis. Additionally, Angiotensin II human TFA triggers apoptosis and encourages capillary formation from endothelial cells through the LOX-1 dependent redox-sensitive pathway [1] [2] [3] [4].

Angiotensin II is a potent direct vasoconstrictor, causing arteries and veins to constrict, so leading to an increase in blood pressure.

Angiotensin II 5-valine TFA is an agonist of angiotensin receptor.

[Sar1, Ile8]-Angiotensin II acetate activates both the NADPH and NADH oxidases, and stimulates superoxide anion formation in vascular smooth muscle cells. [Sar1, Ile8]-Angiotensin II acetate has multiple effects on vascular smooth muscle, including contra

Angiotensin I/II (1-5) is a peptide (ASP-ARG-VAL-TYR-ILE) that contains the amino acids 1-5 and is converted from Angiotensin I/II.

Urotensin II (114-124), human acetate is an 11-amino acid residue peptide, is a potent vasoconstrictor and agonist for the orphan receptor GPR14.

[Sar1, Ile8]-Angiotensin II 3TFA ([Sar1, Ile8]-Angiotensin II 3TFA (37827-06-8(free base))) is a peptide that has multiple effects on vascular smooth muscle.

Angiotensin I/II (1-6) is a peptide (ASP-ARG-VAL-TYR-ILE-HIS) that contains the amino acids 1-6 and is converted from Angiotensin I/II peptide.

[Sar1, Ile8]-Angiotensin II(3TFA) is a peptide that has multiple effects on vascular smooth muscle.

Urotensin II (114-124), human, is an 11-amino acid residue peptide that exhibits strong vasoconstrictor activity and acts as an agonist for the orphan receptor GPR14.

Urotensin II (114-124), human TFA, is an 11-amino acid residue peptide with a strong vasoconstrictor effect. This compound acts as an agonist for the orphan receptor GPR14.

ngiotensin II 5-valine is an angiotensin II analog which is an agonist at angiotensin receptors.

[Tyr(P)4] Angiotensin II is a peptide that exerts a multitude of effects on vascular smooth muscle. These effects include the contraction of normal arteries, as well as the induction of hypertrophy or hyperplasia in cultured cells or diseased vessels.

The substitution with Sar at position 1 of angiotensin II resulted in a partial agonistic activity.

Angiotensin III, human, mouse (Angiotensin III, human, mouse(3TFA))(3TFA) is an endogenous angiotensin II receptor (AT2R) agonist(IC50s of 0.648 nM).

Angiotensin I (human, mouse, rat) is the precursor to the vasoconstrictor peptide angiotensin II, cleaved by the angiotensin-converting enzyme (ACE).Angiotensin is a peptide hormone that causes vasoconstriction and an increase in blood pressure. It is part of the renin–angiotensin system, which regulates blood pressure. Angiotensin also stimulates the release of aldosterone from the adrenal cortex to promote sodium retention by the kidneys.

[Sar1, Ile8]-Angiotensin II (TFA) is a peptide compound that exerts various effects on vascular smooth muscle. These effects include the contraction of normal arteries as well as the hypertrophy or hyperplasia of cultured cells or diseased vessels.

Glucagon-like peptide 2 (GLP-2) is a recently identified intestinal epithelium-specific growth factor that has been shown to reduce the severity of inflammatory disorders of the intestine in rodent models. Currently Glucagon-Like Peptide 2 is used as a po

Human urocortin (hUcn) II is a new member of the corticotropin-releasing-factor (CRF) family. It selectively binds to the CRF2 receptor. Human urocortin II exhibits mild motor-suppressive effects and delayed anxiolytic-like effects，suggesting a time-depen

Human urocortin (hUcn) II is a new member of the corticotropin-releasing-factor (CRF) family. It selectively binds to the CRF2 receptor.

Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity.

(Sar1,Ile4,8)-Angiotensin II is a functionally selective agonist for the angiotensin II type 1 receptor (AT1R), enhancing insulin-stimulated signaling of the insulin receptor (IR) and glycogen synthesis. It boosts the insulin-induced phosphorylation of Akt and GSK3α/β [1].

Angiotensin III, human, mouse (TFA) is an angiotensin.

Pentasarcosyl angiotensin II is a synthetic analog of angiotensin II.

Angiotensin I/II (1-6) TFA is a chemical compound comprising amino acids 1-6. It is derived from the Angiotensin I/II peptide, which is formed by the cleavage of the precursor angiotensinogen by renin. The resulting Angiotensin I is then hydrolyzed by angiotensin-converting enzyme (ACE) to produce biologically active Angiotensin II. Angiotensin II has been extensively studied for its potential applications in the treatment of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy[1][2][3].